A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 507 participants.

Also called NCT01098539

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 507 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01098539
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Brazil, Colombia, Germany, India, Israel, Peru, Philippines, Russia, South Africa, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01098539. Randomized; double masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-11 (actual). Results posted on 2014-05-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
Condition
Diabetes Mellitus, Type 2
Intervention (Biological)
albiglutide
Intervention (Drug)
sitagliptin
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct01098539
Content hash
62cb6aa6d693b3808703130f92cd4c75c42c8a1756c703331c0e48453408ab12